Skip to main content
PMC home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2006 Mar;21(1):34–40. doi: 10.1007/BF02913064

Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate

T Malati 1,✉, G Rajani Kumari 1, P V L N Murthy 2, Ch Ram Reddy 2, B Surya Prakash 2
PMCID: PMC3453769  PMID: 23105567

Abstract

Prostate Specific Antigen (PSA) has emerged as the most applicable and important tumor marker for carcinoma prostate. In the present study PSA was determined in serum of healthy subjects, patients of benign prostate hypertrophy (BPH) and Carcinoma Prostate (Ca−P) to evaluate its diagnostic efficiency in day to day management of prostate cancer patients and in differentiating patients of early prostate cancer from those with BPH. Receiver operating characteristic curve (ROC) revealed 2 ng/ml and 10 ng/ml cut off serum PSA level for BPH and untreated carcinoma prostate patients (Ca−P). An extremely significant increase (P<0.0001) was observed in mean PSA concentration in BPH patients and adenocarcinoma prostate patients when compared to healthy males. Clinical relevance of PSA was highlighted by a case study of cancer patient prior to any therapy till death.

Key words: Total PSA, BPH, Carcinoma Prostate, long term case study

Full Text

The Full Text of this article is available as a PDF (133.9 KB).

References

  • 1.Pienta, Esper Risk factors for prostate cancer. Ann Inter Med. 1993;118:793–803. doi: 10.7326/0003-4819-118-10-199305150-00007. [DOI] [PubMed] [Google Scholar]
  • 2.Morgan T. O., Steven J., Jacobsen W. F., McCarthy D. J., Jacobson D. G., McLeod, Moul J. W. Age Specific reference ranges for serum prostate specific Antigen in Black Men. New Engl. J. Med. 1996;335(5):304–310. doi: 10.1056/NEJM199608013350502. [DOI] [PubMed] [Google Scholar]
  • 3.Kramer B. S., Brown M. L., Prorok P. C., Potosky A., Gohagan J. K. Prostate caner screening: what we know and what we need to know. Ann. Intern. Med. 1993;119:914–923. doi: 10.7326/0003-4819-119-9-199311010-00009. [DOI] [PubMed] [Google Scholar]
  • 4.Malati T., Rajani Kumari G. Racial and Ethnic variation of Prostate Specific Antigen in global population: Age specific reference intervals for serum Prostate Specific Antigen in healthy South Indian males. Ind. J. Clin. Biochem. 2004;19(1):32–137. doi: 10.1007/BF02872408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rajani Kumari G., Malati T. Stability of total and free prostate specific antigen in serum samples at different storage conditions. Ind. J. Clin. Biochem. 2004;19(2):10–13. doi: 10.1007/BF02894250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Malati, T., Rajani Kumari, G., Murthy, P. V. L. N., Rammurthy, S., Aruna Prayag, Rami Reddy, Surya Prakash and Nanda Kumar (2003). The role of Free and Molecular Complexes of PSA, TRUS and DRE in Diagnosis and management of BPH and Prostate Carcinoma. International Proceedings of 22nd World Congress of Pathol. & Lab Medicine, Busan, Korea, Aug 30–Sept 3, 79–88.
  • 7.Kuriyama M., Wanf M. C., Lee C. L., et al. Multiple marker evaluation in prostate cancer with the use of tissue-specific antigen. JNCI. 1982;69:99–105. [PubMed] [Google Scholar]
  • 8.Barak M., Yoel M., Aharon L., Nachran G. Evaluation of prostate specific antigen as marker for adenocarcinoma of the prostate. J. Lab Clin. Med. 1989;113(5):598–603. [PubMed] [Google Scholar]
  • 9.Brawer M. K., Lange P. H. Prostate-specific antigen: its role in early detection, staging and monitoring of prostatic carcinoma. J. Endo Urol. 1989;3:227–227. [Google Scholar]
  • 10.Okihara K., Cheli C. D., Partin A. W., Fritche H. A., Chan D. W., Sokoll L. J., Brawer M. K., Schwartz M. K., Vessella R. L., Loughlin K. R., Johnston D. A., Babaian R. J. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J. Urol. 2002;167(5):2017–2023. doi: 10.1016/S0022-5347(05)65075-6. [DOI] [PubMed] [Google Scholar]
  • 11.Lee F., Trop Pedersen S. T., Carroll J. T., Siders D. B., Christensson D. C., Mitchell A. E. Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasm. Urology. 1989;34:4–4. doi: 10.1016/0090-4295(89)90446-9. [DOI] [PubMed] [Google Scholar]
  • 12.Partin A. W., Carter B. H., Chan D. W., Jonathan Estein, J. I., Oesterling J. E., Rock R. C., Weber J. P., Walch P. C. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 1990;143:747–752. doi: 10.1016/s0022-5347(17)40079-6. [DOI] [PubMed] [Google Scholar]
  • 13.Stamey T. A., Yang N., Hay AR., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med. 1987;317:909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  • 14.Lange P. H., Ercole C. J., Lightner D. J., Fraley E. E., Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 1989;141:873–879. doi: 10.1016/s0022-5347(17)41037-8. [DOI] [PubMed] [Google Scholar]
  • 15.Hudson M. A., Bahnsen R. R., Catalona W. J. Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol. 1989;151:1291–1291. doi: 10.1016/s0022-5347(17)38972-3. [DOI] [PubMed] [Google Scholar]
  • 16.Monda J. M., Barry M. J., Oesterling J. E. Prostate-specific antigen can not distinguish stage T 1a (A1) from benign prostatic hyperplasia. J. Urol. 1994;142:1011–1011. doi: 10.1016/s0022-5347(17)35234-5. [DOI] [PubMed] [Google Scholar]
  • 17.Wodrum D. L., Brawer M. K., Partin A. W., Catalona W. J., Southwick P. C. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J. Urol. 1998;159:5–12. doi: 10.1016/S0022-5347(01)63996-X. [DOI] [PubMed] [Google Scholar]
  • 18.Myrtle F. Normal levels of prostate-specific antigen (PSA) In: Catalona W. J., Coffey D. S., Kaor J.P., editors. Clinical aspects of prostate cancer. New York: Elsevier Science Publishing Co.; 1989. pp. 183–189. [Google Scholar]
  • 19.Ercole C. J., Lange P. H., Mathsen M., Chiou R. K., Reddy P. K., Vessella R. L. Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostate cancer. J. Urol. 1987;138:1181–1181. doi: 10.1016/s0022-5347(17)43543-9. [DOI] [PubMed] [Google Scholar]
  • 20.Cooner W. H., Mosley B. R., Rutherford C. L., Beard J. H., Pond H. S., Terry W. J., Igel T. C., Kidd D. D. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol. 1990;143:1146–1146. doi: 10.1016/s0022-5347(17)40211-4. [DOI] [PubMed] [Google Scholar]
  • 21.Oesterling J. E., Chan D. W., Epstein J. I., Kimball A. W., Brujek D. J., Rock R. G., Brendler C. B., Walch P. C. Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J. Urol. 1988;139:766–766. doi: 10.1016/s0022-5347(17)42630-9. [DOI] [PubMed] [Google Scholar]
  • 22.Stamey T. A., Kabalin J. N., Ferrori M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. 1. Untreated patients. J. Urol. 1989;141:1070–1070. doi: 10.1016/s0022-5347(17)41174-8. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES